An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied every 84 days for 168 days

Trial Profile

An open label, multiple dose Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy and safety of a new GnRH implant (ACINO Goserelin 10.8 mg Implant) applied every 84 days for 168 days

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Jun 2011

At a glance

  • Drugs Goserelin (Primary)
  • Indications Prostate cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 21 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top